R01 AI140287/AI/NIAID NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2019	2
2020	4
2021	8
2022	9
2023	6
2024	5
2025	2

1

New β-Lactam-β-Lactamase Inhibitor Combinations.

Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. Yahav D, et al. Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.

2

Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.

Chua HC, Tam VH. Chua HC, et al. Open Forum Infect Dis. 2022 Dec 16;9(12):ofac626. doi: 10.1093/ofid/ofac626. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540388 Free PMC article. Review.

3

Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.

Phe K, Heil EL, Tam VH. Phe K, et al. J Infect Dis. 2020 Jul 21;222(Suppl 2):S132-S141. doi: 10.1093/infdis/jiaa118. J Infect Dis. 2020. PMID: 32691832 Free PMC article. Review.

4

The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy.

Teran N, Egge SL, Phe K, Baptista RP, Tam VH, Miller WR. Teran N, et al. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0100923. doi: 10.1128/aac.01009-23. Epub 2023 Dec 8. Antimicrob Agents Chemother. 2024. PMID: 38063509 Free PMC article.

5

Comparison of cefiderocol in-vitro susceptibility testing modalities.

Teran NS, Vuong L, Phe K, Lasco TM, Miller WR, Tam VH. Teran NS, et al. J Glob Antimicrob Resist. 2024 Jun;37:100-101. doi: 10.1016/j.jgar.2024.03.011. Epub 2024 Mar 27. J Glob Antimicrob Resist. 2024. PMID: 38552875 Free PMC article. No abstract available.

6

Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates.

Tam VH, Hudson CS, Merlau PR, Shields RK. Tam VH, et al. J Chemother. 2022 Sep;34(5):345-346. doi: 10.1080/1120009X.2021.2004363. Epub 2021 Nov 22. J Chemother. 2022. PMID: 34806561 Free PMC article. No abstract available.

7

Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.

Tam VH, Merlau PR, Hudson CS, Kline EG, Eales BM, Smith J, Sofjan AK, Shields RK. Tam VH, et al. J Antimicrob Chemother. 2022 Oct 28;77(11):3130-3137. doi: 10.1093/jac/dkac294. J Antimicrob Chemother. 2022. PMID: 36031868 Free PMC article.

8

Systematic design of pulse dosing to eradicate persister bacteria.

Singh G, Orman MA, Conrad JC, Nikolaou M. Singh G, et al. PLoS Comput Biol. 2023 Jan 17;19(1):e1010243. doi: 10.1371/journal.pcbi.1010243. eCollection 2023 Jan. PLoS Comput Biol. 2023. PMID: 36649322 Free PMC article.

9

Discerning in vitro pharmacodynamics from OD measurements: A model-based approach.

Kesisoglou I, Tam VH, Tomaras AP, Nikolaou M. Kesisoglou I, et al. Comput Chem Eng. 2022 Feb;158:107617. doi: 10.1016/j.compchemeng.2021.107617. Epub 2021 Dec 16. Comput Chem Eng. 2022. PMID: 35250117 Free PMC article.

10

What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.

Abodakpi H, Wanger A, Tam VH. Abodakpi H, et al. Clin Lab Med. 2019 Sep;39(3):473-485. doi: 10.1016/j.cll.2019.05.006. Epub 2019 Jul 6. Clin Lab Med. 2019. PMID: 31383269 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year